MCID: PRS045
MIFTS: 50

Prostatic Hypertrophy malady

Category: Reproductive diseases

Aliases & Classifications for Prostatic Hypertrophy

About this section

Aliases & Descriptions for Prostatic Hypertrophy:

Name: Prostatic Hypertrophy 10 12 65
Benign Prostatic Hypertrophy 65
 
Prostatic Hyperplasia 65

Classifications:



External Ids:

Disease Ontology10 DOID:11132
UMLS65 C0005001, C1739363, C2937421

Summaries for Prostatic Hypertrophy

About this section
MalaCards based summary: Prostatic Hypertrophy, also known as benign prostatic hypertrophy, is related to hypogonadism and leiomyoma, and has symptoms including prostatismand prostatism. An important gene associated with Prostatic Hypertrophy is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways are Ovarian Infertility Genes and Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics. The drugs finasteride and leuprolide have been mentioned in the context of this disorder. Affiliated tissues include prostate, breast and bone, and related mouse phenotypes are limbs/digits/tail and adipose tissue.

Related Diseases for Prostatic Hypertrophy

About this section

Diseases related to Prostatic Hypertrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 143)
idRelated DiseaseScoreTop Affiliating Genes
1hypogonadism29.8AR, CYP19A1
2leiomyoma28.7AR, CYP19A1, ESR1, KLK3, PGR
3prostate cancer28.0AR, CYP19A1, EGF, EGFR, ESR1, KLK3
4prostatitis11.1
5background diabetic retinopathy10.7AR, KLK3
6acinar cell carcinoma10.6AR, KLK3
7adenofibroma10.6EGFR, PGR
8her2-receptor positive breast cancer10.6EGFR, PGR
9ehlers-danlos syndrome progeroid type10.6AR, KLK3
10high molecular weight kininogen deficiency10.5EGFR, ESR1
11kidney leiomyosarcoma10.5AR, ESR1
12c1 inhibitor deficiency10.5AR, KLK3
13seminal vesicle adenocarcinoma10.5ESR1, KLK3
14diffuse pulmonary fibrosis10.5ESR1, KLK3
15vulval paget's disease10.5AR, ESR1
16syringoma10.5ESR1, PGR
17endocrine organ benign neoplasm10.5ESR1, PGR
18cervical benign neoplasm10.5ESR1, PGR
19large bowel leiomyoma10.5ESR1, PGR
20bile duct cystadenoma10.5ESR1, PGR
21glaucoma iridogoniodysgenesia10.5ESR1, PGR
22venous tributary occlusion of retina10.5ESR1, PGR
23deafness, autosomal dominant 8/1210.5ESR1, PGR
24eccrine acrospiroma10.4AR, PGR
25peroneal nerve paralysis10.4ESR1, PGR
26vulvar squamous papilloma10.4ESR1, PGR
27childhood choriocarcinoma of the ovary10.4ESR1, PGR
28craniofrontonasal dysplasia10.4AR, CYP19A1
29extragonadal nonseminomatous germ cell tumor10.4ESR1, PGR
30dental pulp calcification10.4ESR1, PGR
31postpoliomyelitis syndrome10.4AR, PGR
32vulvar alveolar soft part sarcoma10.4ESR1, PGR
33rectum mucinous adenocarcinoma10.4ESR1, PGR
34follicular basal cell carcinoma10.4ESR1, PGR
35childhood mediastinal neurogenic tumor10.4ESR1, PGR
36apocrine adenosis of breast10.4ESR1, PGR
37siberian tick typhus10.4AR, CYP19A1
38uterine corpus adenosarcoma10.4ESR1, PGR
39exposure keratitis10.4ESR1, PGR
40complete atrioventricular canal10.4AR, CYP19A1
41epilepsy, idiopathic generalized 1110.4AR, CYP19A1
42deep leiomyoma10.4PCNA, PGR
43intraventricular meningioma10.4ESR1, PGR
44large cell acanthoma10.4ESR1, PGR
45breast metaplastic carcinoma10.4ESR1, PGR
46internal auditory canal lipoma10.4ESR1, PGR
47adenosarcoma of the uterus10.4ESR1, PGR
48benign multicystic peritoneal mesothelioma10.4CYP19A1, PGR
49benign prostate phyllodes tumor10.4ADRA1A, AR, KLK3
50benign peritoneal mesothelioma10.4EGFR, ESR1

Comorbidity relations with Prostatic Hypertrophy via Phenotypic Disease Network (PDN):

(show top 50)    (show all 53)
Acute CystitisAcute Kidney Failure
AnthracosisAsbestosis
Bladder DiseaseBladder Neck Obstruction
Chronic Kidney FailureCoronary Artery Disease
Cystitis CysticaCystitis
First-Degree Atrioventricular BlockGeneralized Atherosclerosis
GoutHydronephrosis
Interstitial CystitisIschemic Heart Disease
Left Bundle Branch HemiblockLipoma of Spermatic Cord
Low Compliance BladderNephrolithiasis
Neurogenic BladderParkinson Disease, Late-Onset
Pelvic VaricesPinta Disease
PneumoconiosisPostinflammatory Pulmonary Fibrosis
Primary HyperoxaluriaProstate Cancer
Prostate Carcinoma in SituBalanoposthitis
Epididymo-OrchitisInfected Hydrocele
Male Genital DisordersPenile Disease
Peyronie's DiseaseProstate Calculus
Prostate DiseaseProstatitis
ProstatocystitisSpermatocele
Renal Pelvis CarcinomaRight Bundle Branch Block
SilicosisUreter Cancer
UreterolithiasisUrethral Calculus
Urethral CancerUrethral Stricture
UrethritisUrinary Bladder Cancer

Graphical network of the top 20 diseases related to Prostatic Hypertrophy:



Diseases related to prostatic hypertrophy

Symptoms for Prostatic Hypertrophy

About this section

UMLS symptoms related to Prostatic Hypertrophy:


prostatism

Drugs & Therapeutics for Prostatic Hypertrophy

About this section

Drugs for Prostatic Hypertrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 92)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
SilodosinapprovedPhase 422160970-54-75312125
Synonyms:
KAD 3213
 
KMD 3213
Rapaflo
Urief
2
Tamsulosinapproved, investigationalPhase 4, Phase 3, Phase 1151106133-20-4129211
Synonyms:
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
106133-20-4
5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[(2R)-2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxybenzenesulfonamide
5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-[2-[2-(2-ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide
AC1L2V76
BIDD:GT0261
C07124
C20H28N2O5S
CHEBI:9398
CHEMBL836
CID129211
D08560
DB00706
FT-0082894
Flomax
Flomax (TN)
Flowmax
 
HMS2090P15
Harnal
LS-31578
MolPort-003-850-388
NCGC00167442-01
STK626950
TAMSULOSIN
Tamsolusin
Tamsulon
Tamsulon (TN)
Tamsulosin
Tamsulosin (INN)
Tamsulosin Hydrochloride
Tamsulosin [INN:BAN]
Tamsulosina
Tamsulosina [INN-Spanish]
Tamsulosine
Tamsulosine [INN-French]
Tamsulosinum
Tamsulosinum [INN-Latin]
UNII-G3P28OML5I
YM-617
3
Alfuzosinapproved, investigationalPhase 4, Phase 3, Phase 25081403-80-72092
Synonyms:
(±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide
128707-53-9
81403-68-1 (hydrochloride)
81403-80-7
86163-78-2
AB00514667
AC1L1CWF
Alfusosine
Alfuzosin
Alfuzosin (INN)
Alfuzosin Hydrochloride
Alfuzosin [INN:BAN]
Alfuzosina
Alfuzosina [Spanish]
Alfuzosine
Alfuzosine [French]
Alfuzosinum
Alfuzosinum [Latin]
BPBio1_000357
BRD-A09056319-001-02-2
BRD-A09056319-003-03-6
BSPBio_000323
BSPBio_002646
Bio-0003
C19H27N5O4
CHEBI:51141
CHEMBL709
CID2092
CPD000466340
D07124
DB00346
HMS1922P11
HMS2051I10
HMS2093O06
HSDB 7290
KBio3_001866
 
KBioGR_001616
L001317
LS-70106
MLS000759449
MLS001424027
MolPort-003-666-623
N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide
NCGC00095152-01
NCGC00095152-02
NCGC00095152-03
NCGC00095152-04
NCGC00095152-05
Prestwick0_000322
Prestwick1_000322
Prestwick2_000322
Prestwick3_000322
SAM001246638
SL 77-499
SL 77499
SMR000466340
SPBio_000429
SPBio_002244
SPECTRUM1505263
STK643675
Spectrum2_000505
Spectrum3_001063
Spectrum4_001208
Spectrum5_000817
UNII-90347YTW5F
Uroxatral
Xatral
Xatral (TN)
alfuzosin
alphuzosine
4
DoxazosinapprovedPhase 4, Phase 35474191-85-83157
Synonyms:
1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
74191-85-8
77883-43-3 (mesylate)
AC-11062
AC1L1FAT
AC1Q470P
AC1Q4EXN
AKOS001681453
BPBio1_000963
BRD-A13188892-066-03-3
BSPBio_000875
C06970
C23H25N5O5
CHEBI:4708
CHEMBL707
CID3157
CPD000097306
Cardura
Cardura XL
Cardura XL (TN)
Cardura-1
Cardura-2
Cardura-4
ChemDiv2_005017
D07874
D9815_SIGMA
DB00590
 
Doxazosin
Doxazosin (INN)
Doxazosin Mesylate
Doxazosin [INN:BAN]
Doxazosin mesilate
Doxazosin mesylate
Doxazosina
Doxazosina [Spanish]
Doxazosine
Doxazosine [French]
Doxazosinum
Doxazosinum [Latin]
HMS1383E01
HMS2090C20
I06-1346
IDI1_003732
L000738
LS-110228
Lopac0_000474
MolPort-001-684-491
NCGC00018158-06
NCGC00089775-02
Normothen
Oprea1_259518
Prestwick0_000858
Prestwick1_000858
Prestwick2_000858
Prestwick3_000858
SAM002589981
SPBio_002796
UK 33274
UK-33274
UNII-NW1291F1W8
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
doxazosin
5
Testosteroneapproved, investigationalPhase 4, Phase 3, Phase 247458-22-06013
Synonyms:
(+)-testosterone
(+-)-8-iso-testosterone
(+-)-retrotestosterone
(+-)-testosterone
(17b)-17-hydroxy-androst-4-en-3-one
(17beta)-17-Hydroxyandrost-4-en-3-one
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
13-Iso-testosterone
17-Hydroxy-(17-beta)-androst-4-en-3-one
17-Hydroxy-(17beta)-androst-4-en-3-one
17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one
17-Hydroxy-D4-androsten-3-one
17-Hydroxy-androst-4-en-3-one
17-beta-Hydroxy-delta(sup 4)-androsten-3-one
17-beta-Hydroxyandrost-4-en-3-one
17?-Hydroxy-4-androsten-3-one
17a-Hydroxy-(13a)-androst-4-en-3-one
17a-Hydroxy-13a-androst-4-en-3-one
17a-Hydroxy-14b-androst-4-en-3-one
17a-Hydroxy-androst-4-en-3-one
17b-Hydroxy-(10a)-androst-4-en-3-one
17b-Hydroxy-(13a)-androst-4-en-3-one
17b-Hydroxy-(8a)-androst-4-en-3-one
17b-Hydroxy-(8a,10a)-androst-4-en-3-one
17b-Hydroxy-(9b)-androst-4-en-3-one
17b-Hydroxy-(9b,10a)-androst-4-en-3-one
17b-Hydroxy-13a-androst-4-en-3-one
17b-Hydroxy-8a-androst-4-en-3-one
17b-Hydroxy-D4-androsten-3-one
17b-Hydroxy-androst-4-en-3-on
17b-Hydroxy-androst-4-en-3-one
17b-Hydroxyandrost-4-en-3-one
17b-Hydroxyandrost-4-ene-3-one
17b-Testosterone
17b-hydroxy-4-androsten-3-one
17beta-Hydroxy-3-oxo-4-androstene
17beta-Hydroxy-4-androsten-3-one
17beta-Hydroxy-delta(sup4)-androsten-3-one
17beta-Hydroxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-ene-3-one
17beta-hydroxy-4-androsten-3-one
4-Androsten-17?-ol-3-one
4-Androsten-17beta-ol-3-one
4-Androsten-3-one-17b-ol
4-androsten-17β-ol-3-one
4-androstene-17beta-ol-3-one
46923_FLUKA
46923_RIEDEL
58-22-0
7-beta-Hydroxyandrost-4-en-3-one
8-Iso-testosterone
9b,10a-Testosterone
9b-Testosterone
AA 2500
AC-14899
AC1L1LM0
Andriol
Andro
Andro 100
Andro L.A. 200
AndroGel
Androderm
Androderm (TN)
Androgel
Androgel (TN)
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
Andropatch
Andropository 200
Androsorb
Androst-4-en-17b-ol-3-one
Androst-4-en-17beta-ol-3-one
Androst-4-ene-17b-ol-3-one
Andrusol
Andryl 200
Aveed
Axiron
B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E
BIDD:ER0555
BIM-0061761.0001
Beta Testosterone
Bio-0678
Bio-T-Gel
C00535
CCRIS 574
CDB 111C
CHEBI:17347
CHEMBL386630
CID6013
CMC_13449
COL 1621
CP 601B
CPD000058344
Cristerona T
Cristerone T
D00075
D4-Androsten-17b-ol-3-one
DB00624
Dea No. 4000
Delatest
Delatestryl
Depo-Testadiol
Depo-Testosterone
Depo-Testosterone Cypionate
Depo-testosterone
Depotest
EINECS 200-370-5
Epitestosteron
Everone 200
Fortesta
Geno-Cristaux Gremy
Geno-cristaux Gremy
Geno-cristaux gremy
HMS2052N11
HSDB 3398
Halotensin
Homosteron
Homosterone
Intrinsa
 
LMST02020002
LS-148813
LibiGel
Libigel
Lumitestosteron
MLS000563091
MLS001032098
MLS001306401
MLS002174283
Malerone
Malestrone
Malestrone (amps)
Malogen in Oil
Malogen, Aquaspension Injection
Malogen, aquaspension injection
Mertestate
Metandren
Methyltestosterone
MolPort-002-506-901
NCGC00091018-01
NSC 9700
Natesto nasal gel
Neo-Hombreol F
Neo-Testis
Neo-testis
Neotestis
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Perandren
Percutacrine Androgenique
Percutacrine androgenique
Primotest
Primoteston
Rac-17b-hydroxy-(13a)androst-4-en-3-one
Rac-17b-hydroxy-(8a)-androst-4-en-3-one
Rac-17b-hydroxy-(9b,10a)androst-4-en-3-one
Rac-17b-hydroxy-androst-4-en-3-one
Relibra
Retrotestosterone
S00309
S2033_Selleck
SAM001246921
SMR000058344
SMR001261453
Scheinpharm Testone-Cyp
Striant
Striant (TN)
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
T1500_SIGMA
T5411_FLUKA
T5411_SIGMA
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
Testim
Testim (TN)
Testobase
Testoderm
Testoderm Tts
Testogel
Testoject-50
Testolent
Testolin
Testopel
Testopel Pellets
Testopropon
Testosteroid
Testosteron
Testosterona
Testosterona [INN-Spanish]
Testosterone
Testosterone (JAN/USP)
Testosterone Cypionate
Testosterone Enanthate
Testosterone Gel
Testosterone Heptanoate
Testosterone Hydrate
Testosterone Propionate
Testosterone Undecanoate
Testosterone [Androgenic steroids, anabolic]
Testosterone [INN:BAN]
Testosterone and its esters
Testosterone hydrate
Testosterone solution
Testosteronum
Testosteronum [INN-Latin]
Testostosterone
Testostérone
Testoviron
Testoviron Schering
Testoviron T
Testoxyl
Testred
Testred Cypionate 200
Testrin-P.A
Testro AQ
Testro Aq
Testrone
Testryl
Tostrelle
Tostrex
Trans-Testosterone
UNII-3XMK78S47O
Viatrel
Virilon
Virilon IM
Virormone
Virosterone
Vogelxo
ZINC06500184
beta testosterone
delta(sup 4)-Androsten-17(beta)-ol-3-one
delta4-Androsten-17beta-ol-3-one
delta4-androsten-17b-ol-3-one
testosterone
trans-Testosterone
6
Dutasterideapproved, investigationalPhase 4, Phase 3, Phase 2111164656-23-9152945, 6918296
Synonyms:
(1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
(5.alpha.,17.beta.)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
164656-23-9
AC1L49EM
AC1OCF98
Avodart
Avodart (TN)
Avodart, Dutasteride
Avolve
Bio-0167
C27H30F6N2O2
CHEBI:132773
CHEMBL1200969
CHEMBL283245
CID152945
CID6918296
CID9914880
D03820
 
DB01126
Duagen
Dutasteride
Dutasteride (JAN/USAN/INN)
Dutasteride [USAN]
FT-0080365
GG 745
GG-745
GI 198745
GI-198745
GI-198745X
LS-173584
MolPort-003-666-660
MolPort-003-847-041
N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
NSC740477
S1202_Selleck
UNII-O0J6XJN02I
ZINC03932831
alpha,alpha,alpha,Alpha',alpha',alpha'-hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
7
MethyltestosteroneapprovedPhase 4, Phase 3, Phase 247458-18-46010
Synonyms:
17(alpha)-Methyl-delta(4)-androsten-17(beta)-ol-3-one
17-Methyltestosterone
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17-methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-delta(4)-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-methyl-delta-androsten-17beta-ol-3-one
17alpha-methyltestosterone
17beta-Hydroxy-17-methylandrost-4-en-3-one
 
17α-methyl-Δ4-androsten-17β-ol-3-one
17α-methyltestosterone
4-Androstene-17alpha-methyl-17beta-ol-3-one
Android
Methitest
Methyltestosterone
Methyltestosteronum
Metiltestosterona
NSC-9701
Testred
Testred C-III
Virilon
8
MirabegronapprovedPhase 482223673-61-8
Synonyms:
 
Myrbetriq
9
MivacuriumapprovedPhase 48106791-40-65281042
Synonyms:
(R)-1,2,3,4-Tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (E)-4-octenedioate (2:1)
106791-40-6
106861-44-3
133814-19-4
AC1NQXXZ
AC1NQXZZ
BW B109OU dichloride
BW-B1090U
BW-B109OU
BWB109OU
C07550
C58H80N2O14
CHEMBL984
CID5281042
CID5281080
Chlorure de mivacurium
Chlorure de mivacurium [French]
 
Cloruro de mivacurio
Cloruro de mivacurio [Spanish]
D00763
DB01226
LS-172022
MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER
MIVACURIUM CHLORIDE
Mivacron
Mivacron (TN)
Mivacurii chloridum
Mivacurii chloridum [Latin]
Mivacurium
Mivacurium chloride (USAN/INN)
Mivacurium chloride [USAN:INN:BAN]
NCGC00167469-01
SID50112723
bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate
bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate dichloride
10
AtracuriumapprovedPhase 46564228-79-147319
Synonyms:
1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium]
5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate
64228-79-1
64228-81-5 (besylate)
AB00514743
AC1L2HUF
AC1Q67HR
ATRACURIUM
Atracurium
Atracurium Dibesylate
BPBio1_000011
BRN 1523633
 
BSPBio_000009
C07548
C53H70N2O12
CHEBI:2914
CHEMBL1360
CID47319
DB00732
HMS2090I21
LS-86151
MolPort-005-932-641
Prestwick1_000005
Prestwick2_000005
Prestwick3_000005
SPBio_001930
UNII-2GQ1IRY63P
11
RocuroniumapprovedPhase 4238119302-91-9, 143558-00-3441290
Synonyms:
(2beta,3alpha,5alpha,16beta,17beta)-17-acetoxy-16-(1-allylpyrrolidinium-1-yl)-3-hydroxy-2-(morpholin-4-yl)androstane
143558-00-3
AC1L9AWM
BIDD:GT0360
C07556
CHEBI:8884
CID441290
DB00728
 
Esmeron
HMS2090E03
NCGC00167433-01
Rocuronium
Rocuronium Bromide
Rocuronium bromide
SID50112687
Zemuron
[(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate
12
Dihydrotestosteroneexperimental, illicitPhase 413521-18-615, 10635
Synonyms:
(5a,17b)-17-Hydroxyandrostan-3-one
(5alpha,17beta)-17-hydroxyandrostan-3-one
17-Hydroxy-androstan-3-one
17-Hydroxyandrostan-3-one
17b-Hydroxy-3-androstanone
17beta-Hydroxy-5alpha-androstan-3-one
17beta-Hydroxy-5alpha-androstane-3-one
17beta-Hydroxyandrostan-3-one
17beta-hydroxy-5alpha-androstan-3-one
4,5a-Dihydrotestosterone
4-Dihydrotestosterone
5-a-Androstanolone
5-alpha-Androstanolone
5.alpha.-Dihydrotestosterone
5A-Androstan-3-on-17B-ol
5B-Androstan-3-on-17B-ol
5a-Androstan-17b-ol-3-one
5a-Dihydrotestosterone
5alpha dihydrotestosterone
 
5alpha-Dihydrotestosterone
5alpha-androstan-17beta-ol-3-one
Anaboleen
Anabolex
Andractim
Androlone
Androstalone
Androstan-17b-ol-3-one
Androstan-17beta-ol-3-one
Androstanolone
Cristerona MB
DHT
Dihydrotestosterone
Drolban
Neodrol
Proteina
Protona
Stanaprol
Stanolone
Stanorone
13Adrenergic AgentsPhase 4, Phase 3, Phase 24204
14
Testosterone enanthatePhase 4, Phase 3, Phase 2474315-37-79416
Synonyms:
17-((1-Oxoheptyl)oxy)androst-4-en-3-one
17-Hydroxyandrost-4-en-3-one, 17-heptanoate
17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid
17beta-Enanthoxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-en-3-one enanthate
4-Androsten-17beta-ol-3-one 17-enanthate
4-Androsten-3-one 17beta-enanthate
Androgyn L.A.
Andropository
Androtardyl
Atlatest
DEA No. 4000
DePatestrye
Delatest
Delatestryl
Depo-Testro Med
Ditate
Durathate
Everone
 
Exten test
Malogen L.A.
Malogen L.A.200
Orquisteron-E
Primotestone
Reposo TMD
Testanthate
Testate
Testenate
Testinon
Testoenant
Testonenant
Testosterone 17-enanthate
Testosterone 17beta-heptanoate
Testosterone 17beta-heptanoic acid
Testosterone enantate
Testosterone heptoate
Testosterone heptoic acid
Testosterone heptylate
Testosterone oenanthate
Testostroval
15Testosterone 17 beta-cypionatePhase 4, Phase 3, Phase 2474
16Antihypertensive AgentsPhase 4, Phase 33618
17Neuromuscular AgentsPhase 4, Phase 2, Phase 3922
18Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 318510
19AnestheticsPhase 47385
20Testosterone undecanoatePhase 4, Phase 3, Phase 2474
21Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 19988
22Cholinergic AntagonistsPhase 41423
23Muscarinic AntagonistsPhase 4961
24Neurotransmitter AgentsPhase 4, Phase 3, Phase 214795
25Adrenergic AntagonistsPhase 4, Phase 3, Phase 21253
26Adrenergic alpha-1 Receptor AntagonistsPhase 4, Phase 3, Phase 2405
27Adrenergic alpha-AntagonistsPhase 4, Phase 3, Phase 2586
28Solifenacin succinatePhase 4106242478-38-2
29Cholinergic AgentsPhase 4, Phase 2, Phase 33243
30AndrogensPhase 4, Phase 21162
31Antineoplastic Agents, HormonalPhase 4, Phase 24256
32HormonesPhase 4, Phase 3, Phase 2, Phase 111748
33Anabolic AgentsPhase 4, Phase 2375
34Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 110002
355-alpha Reductase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1155
36Adrenergic beta-3 Receptor AgonistsPhase 487
37Adrenergic AgonistsPhase 42331
38Neuromuscular Nondepolarizing AgentsPhase 4176
39Adrenergic beta-AgonistsPhase 41266
40Neuromuscular Blocking AgentsPhase 4327
41
Magnesium oxideapprovedPhase 3581309-48-414792
Synonyms:
 
Magmitt
Magnesium Oxide
42
Tadalafilapproved, investigationalPhase 3, Phase 2, Phase 1140171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
43
FinasterideapprovedPhase 3, Phase 2, Phase 16498319-26-757363
Synonyms:
(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(tert-butyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
17beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androst-1-en-3-one
34202_FLUKA
34202_RIEDEL
98319-26-7
AB00513901
AC1L1MUF
AC1Q5L2C
Andozac
BPBio1_001027
BRD-K01095011-001-03-5
BRN 4269024
BSPBio_000933
C23H36N2O2
CCRIS 7438
CHEBI:5062
CHEMBL710
CID57363
CPD000466304
Cahill May Roberts Brand of Finasteride
Chibro Proscar
Chibro-Proscar
Chibro-proscar
D00321
D018120
DB01216
DB07774
Eucoprost
F1293_SIGMA
FIT
FT-0082891
Finasterida
Finasterida [INN-Spanish]
Finasteride
Finasteride (USP/INN)
Finasteride [USAN:INN:BAN]
Finasteridum
Finasteridum [INN-Latin]
Finastid
Finpecia
Frosst Iberica Brand of Finasteride
HMS1570O15
 
HMS2051F09
HMS2090G22
HSDB 6793
KS-1058
L-652,931
LS-7397
Lipha Brand of Finasteride
MK 0906
MK 906
MK-0906
MK-906
MK906
MLS000759404
MLS001165768
MLS001424046
MSD Brand of Finasteride
MSD Chibropharm Brand of Finasteride
Merck Brand 1 of Finasteride
Merck Brand 2 of Finasteride
Merck Frosst Brand 1 of Finasteride
Merck Frosst Brand 2 of Finasteride
Merck Sharp & Dhome Brand 2 of Finasteride
Merck Sharp & Dohme Brand 1 of Finasteride
MolPort-002-500-272
N-(2-Methyl-2-propyl)-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxamide
N-(2-methyl-2-propyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-en-17beta-carboxamide
N-tert-Butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
Prestwick0_000717
Prestwick1_000717
Prestwick2_000717
Prestwick3_000717
Propecia
Propecia (TN)
Propeshia
Proscar
Proscar (TN)
Proscar, Propecia, Finasteride
Prostide
S1197_Selleck
SAM001246541
SMR000466304
SPBio_002854
UNII-57GNO57U7G
YM-152
ZINC03782599
finasteride
44
Cetrorelixapproved, investigationalPhase 355120287-85-616129715, 25074887
Synonyms:
120287-85-6
Ac-D-Nal(2)-D-Phe(pCl)-D-Pal(3)-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2
CHEBI:59224
CHEMBL1200490
Cetrorelix
Cetrorelix (INN)
Cetrorelix Acetate
Cetrorelixum
 
Cetrorelixum [INN-Latin]
Cetrotide
Cetrotide (TN)
D07665
HS-2008
N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N5-carbomoyl-D-ornithyl-L-leucyl-L-prolyl-D-alaninamide
N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-L-tyrosyl-N(5)-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide
SB 75
SB-75
45
MetforminapprovedPhase 31645657-24-9, 1115-70-414219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMBG
DMGG
Diabefagos
Diabetosan
Diabex
Diaformin
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Meguan
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin Hydrochloride
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
Obimet
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
46
Inulinapproved, nutraceuticalPhase 3959005-80-524763
Synonyms:
(2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-2-[[(2R,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethy
189444-25-5
887747-94-6
AC1L2NNM
AI3-19506
CID24763
DB00638
 
EINECS 232-684-3
INULIN
Inulin USP 27
Inulin [BAN]
Inulin and sodium chloride
Inulin from Jerusalem artichokes
LS-186416
LS-187349
47
AcetylcholineexperimentalPhase 2, Phase 368951-84-3187
Synonyms:
ACh
Acetyl choline ion
Acetylcholine Chloride
Acetylcholine cation
 
Acetylcholinium: acetyl-Choline
Choline acetate
Choline acetate (ester)
Miochol E
O-Acetylcholine
acetylcholine chloride
48Pharmaceutical SolutionsPhase 2, Phase 37004
49Hypoglycemic AgentsPhase 34503
50OnabotulinumtoxinAPhase 2, Phase 3588

Interventional clinical trials:

(show top 50)    (show all 79)
idNameStatusNCT IDPhase
1Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate HypertrophyCompletedNCT00542165Phase 4
2Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic HyperplasiaCompletedNCT00771394Phase 4
3Safety and Efficacy of QD Versus BID Silodosin With Lower Urinary Tract Symptoms Suggestive of BPHCompletedNCT01260129Phase 4
4Efficacy Study for Use of Dutasteride (Avodart) With Testosterone ReplacementCompletedNCT00752869Phase 4
5Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate CancerCompletedNCT00375765Phase 4
6Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic ObstructionCompletedNCT00827814Phase 4
7Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate EnlargementCompletedNCT01294592Phase 4
8Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate EnlargementCompletedNCT00648323Phase 4
9TRADE-Testosterone Replacement and Dutasteride EffectivenessCompletedNCT00194675Phase 4
10Alpha-Blockers in Allergic Rhinitis (MAN 01)CompletedNCT01946035Phase 4
11Study to Assess the Efficacy of Medi-Tate TIND DeviceRecruitingNCT02145208Phase 4
12A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)RecruitingNCT02656173Phase 4
13Effect of Deep BLock on Intraoperative Surgical ConditionsRecruitingNCT01631149Phase 4
14Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 YearsRecruitingNCT02757963Phase 4
15Efficacy of Prunus Domestica Extract in BPHActive, not recruitingNCT02702947Phase 4
16The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the ProstateCompletedNCT00427219Phase 2, Phase 3
17Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)CompletedNCT00663858Phase 3
18Clinical Trial in Males With BPH (Enlarged Prostate)CompletedNCT00029822Phase 3
19Medical Therapy of Prostatic Symptoms (MTOPS)CompletedNCT00021814Phase 3
20Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)CompletedNCT00670306Phase 3
21"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskCompletedNCT00056407Phase 3
22A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary SymptomsCompletedNCT01139762Phase 3
23Intraprostatic Botulinum Toxin Type "A" Injection in Patients With Benign Prostatic Hyperplasia and Unsatisfactory Response to Medical TherapyCompletedNCT01566292Phase 2, Phase 3
24Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic SyndromeCompletedNCT02778776Phase 3
25A-botulinic Toxin for Symptomatic Benign Prostate HypertrophyActive, not recruitingNCT01275521Phase 3
26H-36731: Finasteride in Management of Elevated Red Blood CellsNot yet recruitingNCT02548117Phase 3
27Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)TerminatedNCT00449150Phase 3
28JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)TerminatedNCT01830829Phase 3
29Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS)TerminatedNCT00688948Phase 2, Phase 3
30Vardenafil in Greenlight(TM) Laser Surgery of Benign Prostate HypertrophyCompletedNCT00461123Phase 2
31Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)CompletedNCT00037141Phase 1, Phase 2
325-Alpha Reductase and Anabolic Effects of TestosteroneCompletedNCT00475501Phase 2
33Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic HyperplasiaCompletedNCT00386009Phase 2
34A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After SupplementationCompletedNCT00154843Phase 2
35Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous ChorioretinopathyCompletedNCT01227993Phase 1, Phase 2
36Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral TestosteroneCompletedNCT00161421Phase 2
37Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)RecruitingNCT02676544Phase 1, Phase 2
38Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 GramsRecruitingNCT02396420Phase 2
39Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate BrachytherapyRecruitingNCT01446991Phase 2
40A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).RecruitingNCT00044226Phase 2
41Testosterone Plus Finasteride Treatment After Spinal Cord InjuryNot yet recruitingNCT02248701Phase 2
42A Study in Men With Benign Prostatic HyperplasiaTerminatedNCT01097707Phase 2
43A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)TerminatedNCT00651807Phase 2
44Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)CompletedNCT01330927Phase 1
45Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic HyperplasiaRecruitingNCT02592473Phase 1
46A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male SubjectsNot yet recruitingNCT02615782Phase 1
47Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: MarketscanCompletedNCT01323998
48Plasmakinetic Enucleation of the Prostate to Treat Benign Prostatic Hypertrophy Patients With Large ProstateCompletedNCT01637701
49MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate CancerCompletedNCT00706966
50Assessing the Impact of the PVP With Greenlight Laser Using Prostatic MRI and Contrast-enhanced UltrasoundCompletedNCT01732991

Search NIH Clinical Center for Prostatic Hypertrophy

Inferred drug relations via UMLS65/NDF-RT43:

Genetic Tests for Prostatic Hypertrophy

About this section

Anatomical Context for Prostatic Hypertrophy

About this section

MalaCards organs/tissues related to Prostatic Hypertrophy:

33
Prostate, Breast, Bone, Lung, Liver, Ovary, Thyroid

Animal Models for Prostatic Hypertrophy or affiliated genes

About this section

MGI Mouse Phenotypes related to Prostatic Hypertrophy:

38 (show all 13)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053718.6AR, EGFR, ESR1, FGF8, PGR
2MP:00053758.4AR, CYP19A1, EGFR, ESR1, PCNA
3MP:00053678.1ADRA1A, AR, CYP19A1, EGFR, ESR1, FGF8
4MP:00107717.8AR, CYP19A1, EGF, EGFR, ESR1, PGR
5MP:00053907.8AR, CYP19A1, EGFR, ESR1, FGF8, PGR
6MP:00053817.6AR, CYP19A1, EGF, EGFR, ESR1, FGF8
7MP:00053697.6ADRA1A, AR, CYP19A1, EGFR, ESR1, FGF8
8MP:00053857.4ADRA1A, AR, CYP19A1, EGFR, ESR1, FGF8
9MP:00028737.3AR, CYP19A1, EGF, EGFR, ESR1, FGF8
10MP:00053977.0AR, CYP19A1, EGFR, ESR1, FGF8, PCNA
11MP:00053796.9AR, CYP19A1, EGF, EGFR, ESR1, FGF8
12MP:00053896.8AR, CYP19A1, EGF, EGFR, ESR1, FGF8
13MP:00053876.3AR, CYP19A1, EGF, EGFR, ESR1, FGF8

Publications for Prostatic Hypertrophy

About this section

Articles related to Prostatic Hypertrophy:

(show top 50)    (show all 530)
idTitleAuthorsYear
1
Re: Editorial comment on constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial: S. A. Kaplan J Urol 2013; 190: 1818-1819. (24892642)
2014
2
Tadalafil and benign prostatic hypertrophy. Too risky. (24860894)
2014
3
American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. (22123290)
2012
4
Testosterone levels in benign prostatic hypertrophy and prostate cancer. (18362481)
2008
5
Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study? (16412808)
2006
6
Consensus conference about imaging of Benign Prostatic Hypertrophy. (16200040)
2005
7
Quality improvement activities in prostatectomy for benign prostatic hypertrophy. (12698520)
2003
8
Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy. (12534901)
2002
9
Ammonium-chloride-induced prostatic hypertrophy in vitro: urinary ammonia as a potential risk factor for benign prostatic hyperplasia. (10550527)
1999
10
Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice. (9393292)
1997
11
Detection of bladder tumor by urine cytology in cases of prostatic hypertrophy. (8989544)
1996
12
Laser ablation of prostatic hypertrophy. (7544883)
1995
13
Microwave hyperthermia in benign prostatic hypertrophy: a controlled clinical trial. (7544207)
1995
14
Objective noninvasive evaluation of benign prostatic hypertrophy. (7535622)
1995
15
Short-term oral treatment of canine benign prostatic hypertrophy with chlormadinone acetate. (7538794)
1995
16
Benign prostatic hypertrophy. Options for management. (7518555)
1994
17
New treatments for benign prostatic hypertrophy. (7527259)
1994
18
Technology briefs from the Conseil d'Evaluation des Technologies de la SantAc du QuAcbec (CETS). Diathermy and balloon dialatation treatment of benign prostatic hypertrophy. (7507097)
1993
19
Minimally invasive therapy in bladder outflow obstruction due to benign prostatic hypertrophy. A review of prostatic balloon dilatation and stenting. (7689316)
1993
20
Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy. (7679580)
1993
21
Urinary flow rate in benign prostatic hypertrophy in relation to the degree of obstruction of the vesical outlet. (1373665)
1992
22
Subjective and clinical results after transurethral resection and suprapubic prostatectomy in benign prostatic hypertrophy. (1726084)
1991
23
Dynamics of micturition in benign prostatic hypertrophy patients with compensated obstruction of the vesical outlet: a denervation supersensitivity-related energy-saving mechanism. (1719245)
1991
24
Endocrine treatment of benign prostatic hypertrophy: current concepts. (1702565)
1991
25
Prazosin: an evaluation of its clinical efficacy and safety in the treatment of benign prostatic hypertrophy. (1690475)
1990
26
Re: Bladder outflow tract obstruction and urinary retention from benign prostatic hypertrophy treated by balloon dilatation. (1699630)
1990
27
The effect of bromocriptine in benign prostatic hypertrophy and vesicosphincteric dynamics. (2444307)
1987
28
Development of benign prostatic hypertrophy estimated from ultrasonic measurement with long-term follow up. (2437669)
1987
29
Circulating levels of inhibin, prolactin, TSH, LH, and FSH in benign prostatic hypertrophy before and after tumor resection. (2436203)
1987
30
Specific binding of [3H]-methyltrienolone to both progestin and androgen binding components in human benign prostatic hypertrophy (BPH). (88546)
1979
31
Serum dihydrotestosterone in patients with benign prostatic hypertrophy. (73397)
1977
32
Using antiandrogen therapy in benign prostatic hypertrophy. (66171)
1977
33
The effect of bromocriptine in patients with benign prostatic hypertrophy. (57815)
1976
34
Correlations between clinical findings and urinary flow rate in benign prostatic hypertrophy. (61184)
1976
35
Intracellular localisation of 5alpha-dihydrotestosterone in human benign prostatic hypertrophy. (63340)
1976
36
Urinary flow rate in benign prostatic hypertrophy. (56317)
1976
37
The effect of a 6FG urethral catheter on urinary flow in benign prostatic hypertrophy. (61185)
1976
38
In vivo uptake and metabolism of 3-h-5alpha-androstane-3alpha,17beta-diol and of 3-h-5alpha-androstane-3beta,17beta-diol by human prostatic hypertrophy. (49141)
1975
39
Flat epithelial changes in the urinary bladder in patients with prostatic hypertrophy. (4118752)
1972
40
Therapy with progestational agents in advanced benign prostatic hypertrophy. (4187537)
1969
41
Treatment of benign prostatic hypertrophy with progestational agents: a preliminary report. (4172531)
1968
42
Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. (4143704)
1966
43
TREATMENT OF BENIGN PROSTATIC HYPERTROPHY WITH HYDROXYPROGESTERONE CAPROATE: EFFECT ON CLINICAL SYMPTOMS, MORPHOLOGY, AND ENDOCRINE FUNCTION. (14304354)
1965
44
VOIDING PRESSURE AND URINARY FLOW IN PROSTATIC HYPERTROPHY AND IN NEUROGENIC BLADDER DISORDERS. (14227133)
1964
45
Prostatic hypertrophy in Indonesia. (13919435)
1962
46
Sex chromatin in cells of prostatic hypertrophy and prostatic cancer. (13364266)
1956
47
Benign prostatic hypertrophy. (13346266)
1956
48
Transurethral, perineal, and retropubic prostatectomy; an analysis of 300 operations performed for the correction of benign prostatic hypertrophy. (14836118)
1951
49
Prostatic hypertrophy. (18148544)
1949
50
Benign prostatic hypertrophy, with obstruction. (18899249)
1948

Variations for Prostatic Hypertrophy

About this section

Expression for genes affiliated with Prostatic Hypertrophy

About this section
Search GEO for disease gene expression data for Prostatic Hypertrophy.

Pathways for genes affiliated with Prostatic Hypertrophy

About this section

Pathways related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 17)
idSuper pathwaysScoreTop Affiliating Genes
19.6CYP19A1, PGR
29.6CYP19A1, ESR1
3
Show member pathways
9.5AR, ESR1, KLK3
4
Show member pathways
9.4AR, ESR1, PGR
59.3AR, EGFR, KLK3
69.0EGF, EGFR
7
Show member pathways
9.0EGF, EGFR
8
Show member pathways
9.0EGF, EGFR
99.0EGF, EGFR
109.0EGF, EGFR
119.0EGF, EGFR
128.7AR, CYP19A1, EGFR, ESR1
138.6EGF, EGFR, ESR1
14
Show member pathways
8.4AR, EGF, EGFR, KLK3
15
Show member pathways
7.9AR, EGF, EGFR, FGF8, KLK3
167.9AR, EGF, EGFR, FGF8, KLK3
177.8AR, EGF, EGFR, ESR1, PCNA

GO Terms for genes affiliated with Prostatic Hypertrophy

About this section

Biological processes related to Prostatic Hypertrophy according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of catenin import into nucleusGO:00354139.6EGF, EGFR
2transcription initiation from RNA polymerase II promoterGO:00063679.5AR, ESR1, PGR
3positive regulation of ERK1 and ERK2 cascadeGO:00703749.4ADRA1A, ESR1, FGF8
4ERBB2 signaling pathwayGO:00381289.3EGF, EGFR
5positive regulation of phosphorylationGO:00423279.0AR, EGF, EGFR
6cell proliferationGO:00082839.0AR, EGFR, PCNA
7phosphatidylinositol-mediated signalingGO:00480158.9EGF, EGFR, FGF8
8phosphatidylinositol phosphorylationGO:00468548.9EGF, EGFR, FGF8
9peptidyl-tyrosine phosphorylationGO:00181088.8EGF, EGFR, FGF8
10negative regulation of epidermal growth factor receptor signaling pathwayGO:00420598.7EGF, EGFR
11Ras protein signal transductionGO:00072658.4EGF, EGFR, FGF8

Sources for Prostatic Hypertrophy

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet